AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Praxis Completes FDA Meeting for Tremor Treatment, Reports Positive Results for Epilepsy Drug
ByAinvest
Thursday, Dec 4, 2025 5:30 pm ET1min read
Praxis Precision Medicine has completed its pre-new drug application meeting with the FDA for its essential tremor treatment, ulixacaltamide. The company expects to file the NDA in early 2026. Praxis also reported positive results from a Phase 2 study evaluating relutrigine for developmental and epileptic encephalopathies, with a well-tolerated safety profile and improvement in motor seizures. The FDA has confirmed a meeting to review the data, with the company to determine the timeline for filing an NDA after the meeting.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet